Conducting cost-effectiveness analyses of type 2 diabetes in low- and middle-income countries: Can locally generated observational study data overcome methodological limitations?

Diabetes Research and Clinical Practice

Volumn 88, Issue SUPPL. 1, 2010, Pages S17-S22

  Baik, SeiHyun ^a   Chacra, Antônio Roberto ^b   Yuxiu, Li ^c   White, Jeremy ^d   Güler, Serdar ^e   Latif, Zafar A ^f  

^a Korea University College of Medicine   (South Korea)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d Novo Nordisk FemCare AG   (Switzerland)

^e ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^f Bangladesh Institute of Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders   (Bangladesh)

Author keywords

Cost effectiveness analyses; Health economic models; Observational studies; Type 2 diabetes

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL STUDY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; GOLD STANDARD; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; INTERMETHOD COMPARISON; LOWEST INCOME GROUP; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RESOURCE ALLOCATION;

EID: 77952733674     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(10)70004-8     Document Type: Article

References (36)

1. International Diabetes Federation. 2009. (accessed Nov, 2009). http://www.idf.org/new-international-diabetes-federation-study-reveals-people-developing-countries-pay-more-diabetes-ca.
2. Arredondo A, Zuniga A Economic consequences of epidemiological changes in diabetes in middle-income countries. Diabetes Care 2004, 27:104-109.
3. Unwin N, Alberti KG Chronic non-communicable diseases. Ann. Trop. Med. Parasitol. 2006, 100:455-464.
4. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007, 370:1929-1938.
5. Roglic G, Unwin N Mortality attributable to diabetes: Estimates for the year 2010. Diabetes Res. Clin. Pract. 2010, 87:15-19.
6. Adeyi O, Smith O, Robles S Improving NCD outcomes: A public policy perspective. 'Public policy and the challenge of chronic noncommunicable diseases'. Part 976 2007, World Bank, Washington DC.
7. Ringborg A, Cropet C, Jonsson B, Gagliardino JJ, Ramachandran A, Lindgren P Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int. J. Clin. Pract. 2009, 63:997-1007.
8. Bagust A, Hopkinson PK, Maier W, Currie CJ An economic model of the long-term health care burden of type II diabetes. Diabetologia 2001, 44:2140-2155.
9. Bottomley JM, Raymond FD Pharmaco-economic issues for diabetes therapy. Best Pract. Res. Clin. Endocrinol. Metab. 2007, 21:657-685.
10. Garrido MV, Kristensen FB, Nielsen CP, Busse R Health technology assessment and health policy making in Europe. Current status, challenges and potential. World Health Organization on behalf of the European Observatory on Health Systems and Policies http://www.euro.who.int/Document/E91922.pdf.
11. Scott A, Currie N, Donaldson C Evaluating innovation in general practice: a pragmatic framework using programme budgeting and marginal analysis. Family Practice 1998, 15:216-222.
12. Banerjee S, Tran K, Li H, Cimon K, Daneman D, Simpson S, et al. Short-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of costeffectiveness [Technology Report no 87] 2007, Canadian Agency for Drugs and Technologies in Health, Ottawa.
13. Kirigia JM, Sambo HB, Sambo LG, Barry SP Economic burden of diabetes mellitus in the WHO African region. BMC Int. Health Hum. Rights 2009, 9:6.
14. World Health Organization CHOosing Interventions that are Cost-Effective (WHO-CHOICE) http://www.who.int/choice/costs/CER_thresholds/en/index.html.
15. Yang B-M The future of healthcare technology assessment in healthcare decision making in Asia. Pharmacoeconomics 2009, 27:891-901.
16. Freemantle N, Hessel F The applicability and generalizability of findings from clinical trials for health-policy decisions. Pharmacoeconomics 2009, 27:5-10.
17. Drummond MF, Grima D Multinational economic studies: Lessons learned from trial-based and modelling studies. Value in Health 2008, 4:192.
18. Silverman SL From randomized controlled trials to observational studies. Am. J. Med. 2009, 122:114-120.
19. Drummond MF Experimental versus Observational Data in the Economic Evaluation of Pharmaceuticals. Med. Decis. Making 1998, 18:S12-S18.
20. Dixon S, Peters JR Evaluating the 'real' costeffectiveness of health technology: reconciling the public interest with patients' interests. Curr. Med. Res. Opin. 2007, 23:S1-S6.
21. Drummond MF Making economic evaluations more accessible to healthcare decision-makers. Eur. J. Health Econ. 2003, 4:246-247.
22. Khaw KT, Day N, Bingham S, Wareham N Observational versus randomized trial evidence. Lancet 2004, 364:753-754.
23. Lawlor DA, Smith G Davey, Kundu D, Bruckdorfer KR, Ebrahim S Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?. Lancet 2004, 363:1723-1727.
24. Coyle D, Lee KM, O'Brien BJ The role of models within economic analysis focus on type 2 diabetes mellitus. Pharmacoeconomics 2002, 20:11-19.
25. Reeves BC Limitations of analyses of effectiveness using observational data. Eur. Heart J. 2006, 27:1642-1643.
26. Lee KH, Seo SJ, Smith-Palmer J, et al. Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea. Value in Health 2009, 12:S55-S61.
27. Garrido MV, Mangiapane S Surrogate outcomes in health technology assessment: An international comparison. Int. J. Technol. Assess Health Care 2009, 25:315-322.
28. Taylor RS, Elston J The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. Health Technol. Assess. 2009, 13:1-88.
29. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol. Assess. 2004, 8:1-213.
30. Drummond MF, Manca A, Sculpher M Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies. Int J. Technol. Assess. Health Care 2005, 21:165-171.
31. Baltussen R, Leidl R, Ament A Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making. Pharmacoeconomics 1999, 16(5 Pt 1):449-458.
32. Gray AM, Clarke P The economic analyses of the UK prospective diabetes study. Diabet. Med. 2008, 25:47-51.
33. Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, et al. Cost-Effectiveness of Switching to Biphasic Insulin Aspart in Poorly-Controlled Type 2 Diabetes Patients in China. Adv. Ther. 2008, 25:752-774.
34. Eggleston KN, Shah ND, Smith SA, Wagie AE, Williams AR, Grossman JH, et al. The net value of health care for patients with type 2 diabetes, 1997 to 2005. Ann. Intern. Med. 2009, 151:386-393.
35. The Mount Hood 4 Modeling Group Computer modelling of diabetes and its complications. A report on the fourth Mount Hood Challenge Meeting. Diabetes Care 2007, 30:1638-1646.
36. Eddy DM, Schlessinger L Validation of the archimedes diabetes model. Diabetes Care 2003, 26:3102-3110.